Aromatase Inhibitors and Bone Loss: Risks in Perspective
- 1 August 2005
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (22), 4847-4849
- https://doi.org/10.1200/jco.2005.03.903
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Status Report 2004Journal of Clinical Oncology, 2005
- Effects of the Steroidal Aromatase Inhibitor Exemestane and the Nonsteroidal Aromatase Inhibitor Letrozole on Bone and Lipid Metabolism in Ovariectomized RatsClinical Cancer Research, 2004
- A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast CancerNew England Journal of Medicine, 2004
- Osteopenia and osteoporosis in women with breast cancerSeminars in Oncology, 2003
- American Society of Clinical Oncology 2003 Update on the Role of Bisphosphonates and Bone Health Issues in Women With Breast CancerJournal of Clinical Oncology, 2003
- Aromatase Inhibitors in Breast CancerNew England Journal of Medicine, 2003
- Osteoporosis Due to Cancer Treatment: Pathogenesis and ManagementJournal of Clinical Oncology, 2000
- Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 StudyJNCI Journal of the National Cancer Institute, 1998
- Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women.Journal of Clinical Oncology, 1996
- Effects of Tamoxifen on Bone Mineral Density in Postmenopausal Women with Breast CancerNew England Journal of Medicine, 1992